LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $30.60m
- $17.28m
- $0.17m
Lisata Therapeutics Inc expected to post a loss of 89 cents a share - Earnings Preview
Brief: Lisata Therapeutics Announces First Patient Treated In Phase 2A Trial Of Lsta1
Brief: Lisata Therapeutics Announces Completion Of Enrollment In Phase 2B Ascend Trial Of Lsta1
Lisata Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Lisata Therapeutics Q3 EPS USD -0.65
Lisata Therapeutics Inc expected to post a loss of 93 cents a share - Earnings Preview
Brief: Lisata Therapeutics Report First Patient Treated in Cholangiocarcinoma Cohort Of The BOLSTER Trial Of LSTA1
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Lisata Therapeutics up on EMA orphan tag for cancer drug candidate
Brief: Lisata Therapeutics Announces First Patient Treated In Bolster Trial Of Lsta1, A Novel Tumor-Targeting And Penetrating Peptide, In Patients With Advanced Solid Tumors
Brief: Lisata Therapeutics Announces Outcome Of Interim Futility Analysis For Its Phase 2B Trial Of LSTA1 In Metastatic Pancreatic Ductal Adenocarcinoma
Brief: Lisata Therapeutics Q2 EPS USD -0.5
Lisata Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Lisata Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Amgen, New York Times, Jacobs Solutions
U.S. STOCKS ON THE MOVE-Organon, Bio-Techne, TransDigm
U.S. STOCKS ON THE MOVE-DISH Network, Lisata Therapeutics, WeightWatchers
Brief: Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted To LSTA1 For The Treatment Of Malignant Glioma
Lisata Therapeutics up as FDA grants orphan drug tag to cancer drug candidate